

Appendix 6

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket No: 018733/0874

In re parent application of

Shiu-on LEUNG et al

Group Art Unit: 1642

Serial No. 09/155,106

Examiner: C. Yasen

Filed: November 17, 1998

For: HUMANIZATION OF AN ANTI-CARCINOEMBRYONIC ANTIGEN ANTI-IDIOTYPE ANTIBODY AND USE AS A TUMOR VACCINE AND FOR TARGETING APPLICATIONS

DECLARATION UNDER 37 C.F.R. §1.132

I, David Milton Goldenberg, declare that:

1. I am the Chairman of the Board and founder of Immunomedics, Inc., where I have been employed since 1983. I have remained Chairman since the inception of the Company, and have at various times also been Chief Executive Officer and President. I also am the President and founder of the Center for Molecular Medicine and Immunology (CMMI), as well as its clinical unit, the Garden State Cancer Center, both constituting non-profit research centers located in Belleville, New Jersey. I have been President of CMMI since 1983, and incorporated this institution in 1982.

2. On or d prior to March 20, 1996, the filing date of the priority document, U.S. Serial No. 60/013,703, of PCT/US97/04696, filed on March 19, 1997, to which the above-captioned application claims priority, the hybridoma that produces the rat anti-idiotype antibody (rWI2) against a Class III, anti-CEA murine monoclonal antibody, MN-14, was a proprietary cell line owned and possessed by Immunomedics, Inc., and researched exclusively by Immunomedics and CMMI investigators in collaborative projects. Thus, the DNA encoding rWI2 was not available to the public prior to the priority date of the above-captioned application.

3. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date

Dec. 2, 2003


David Milton Goldenberg